Scarica l'app Stockscreener
2.05
7.66%
-0.17
Pre-mercato:
2.08
0.03
+1.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Esperion Therapeutics, Inc. (ESPR) Latest Stock News & Headlines - Yahoo Finance
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference - Yahoo Finance
Personalized treatments advance as Esperion Therapeutics urges broader use of hsCRP in heart care - Traders Union
Esperion Therapeutics, Inc. (ESPR) latest stock news and headlines - Yahoo Finance Singapore
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN
Guidance Update: What is the next catalyst for Esperion Therapeutics Inc2026 Drop Watch & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Movement Recap: What are Esperion Therapeutics Incs technical support levels2026 Price Targets & Weekly Return Optimization Alerts - baoquankhu1.vn
ESPR Forecast, Price Target & Analyst Ratings | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics Stock Dips After Q4 Earnings Miss Expectations - StocksToTrade
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ann Arbor pharmaceutical company acquires nasal spray treatment manufacturer - MLive.com
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co. - MarketBeat
This Cheap $2.60's Stock Is A Great Investment With Huge Guideline News. Top 3 Analysts Say Strong Buy $9 to $16 - Moomoo
ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Esperion Therapeutics, Inc. (ESPR) stock price, news, quote and history - Yahoo Finance UK
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio - The Globe and Mail
Esperion sells Japan royalty rights for $50 million to Athyrium By Investing.com - Investing.com Canada
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Sahm
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - The Manila Times
Athyrium Capital Management and Esperion Therapeutics Inc. (NASDAQ: ESPR) have signed a Japanese royalty financing agreement worth $50 million - Bitget
Esperion Therapeutics Enters First Amendment To Credit Agreement On April 2, 2026SEC Filing - TradingView — Track All Markets
Esperion Therapeutics, Athyrium Capital Management Sign $50 Million Japan Royalty Financing - marketscreener.com
Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics. - Bitget
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund. - Bitget
Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy - TradingView — Track All Markets
Esperion (ESPR) acquires Corstasis, adds $25M term loan and $50M royalty sale - Stock Titan
Esperion sells Japan royalty rights for $50 million to Athyrium - Investing.com
Esperion completes acquisition of Corstasis Therapeutics - Investing.com
Athyrium Capital Management and Esperion Enter Into $50 - GlobeNewswire
Esperion Therapeutics ranks 88 among 300 on Americas Fastest Growing Companies list - Traders Union
Zacks Research Has Negative Forecast for ESPR Q2 Earnings - MarketBeat
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) - Bitget
Esperion Presents New Data from CLEAR Outcomes Highlighting Value of Bempedoic Acid at ACC.26 - dicardiology.com
Esperion Therapeutics, Inc. completed the acquisition of Corstasis Therapeutics Inc. - marketscreener.com
New Analyst Updates: $9 and $16 Price Targets on Esperion Therapeutics Signal Major Upside From $2.63 - Moomoo
Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst - MarketBeat
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing - citybiz
Esperion Therapeutics Inc (ESPR) strengthens business outlook amid strategic agreements - MSN
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Bitget
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.7%Here's What Happened - MarketBeat
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Investors can watch Esperion at Needham's virtual healthcare event - Stock Titan
US Market Wrap: Can Esperion Therapeutics Inc outperform under higher oil prices2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Needham Virtual Healthcare Conference features Esperion Therapeutics at 25th anniversary session - Traders Union
Esperion reports bempedoic acid cut ischemic stroke risk by 22% - Investing.com Canada
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 - Bitget
Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session - Traders Union
Esperion Showcases New Data from CLEAR Outcomes - GlobeNewswire
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026 - Yahoo Finance
1.06%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):